In therapeutic applications, for example, excitatory DREADDs can be used to increase the activity of neurons in the LPFC-CdN pathway in order to ameliorate the hypoactivity of the LPFC seen in schizophrenia. This evidence concerns the gene NT5C and schizophrenia.